Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 2 Mar 2023 |
| Orion Corporation: Managers' transactions - Liisa Hurme | 2 Mar 2023 |
| Orion Corporation: Managers' transactions - Jari Karlson | 2 Mar 2023 |
| Orion Corporation: Managers' transactions - Juhani Kankaanpää | 2 Mar 2023 |
| Orion Corporation: Managers' transactions - Niclas Lindstedt | 2 Mar 2023 |